Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Imsidolimab (ANB019) in Hidradenitis Suppurativa
2021-001440-99Phase 2Terminated
- Sponsor
- AnaptysBio, Inc.
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Imsidolimab with Placebo (2 arms). Primary endpoint: Change from Baseline in AN count at Week 16. Started Jun 2021; status: terminated.
02
Drugs
imsidolimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2021-001440-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001440-99.